Authors
Yusuke Higuchi, Hiro Tatetsu, Taichi Hirano, Takafumi Shichijo, Asami Yamada, Shikiko Ueno, Tatsuya Takezaki, Junichiro Kuroda, Naoki Shinojima, Kisato Nosaka, Akitake Mukasa, Jun-Ichirou Yasunaga
Published in
International journal of hematology. Aug 19, 2026. Epub Aug 19, 2026.
Abstract
Primary and secondary central nervous system lymphomas (PCNSL and SCNSL, respectively) are aggressive non-Hodgkin lymphomas with high relapse risk. Methotrexate rarely achieves durable remission, necessitating combination therapy or consolidation. Although high-dose busulfan and thiotepa (BuTT) conditioning followed by autologous stem cell transplantation (ASCT) is a promising consolidation strategy, the optimal timing and real-world outcomes of ASCT remain unclear. We retrospectively analyzed 12 patients (eight with PCNSL and four with SCNSL) treated with BuTT/ASCT at a single center between 2019 and 2024. Nine patients underwent upfront ASCT shortly after achieving complete remission with rituximab, methotrexate, procarbazine, and vincristine and remained in remission at a median follow-up of 681 days (range, 147-1322 days). Three patients (two with PCNSL and one with SCNSL) who underwent salvage ASCT following multiple prior therapies experienced early relapse (51-125 days post-ASCT) and died of their disease. BuTT/ASCT is highly effective when administered promptly after remission, whereas salvage ASCT after multiple therapies is associated with poor outcomes. Timely clinical decision-making and upfront consolidation may be key to optimizing the therapeutic benefits of ASCT in CNSL, although further validation is warranted.
PMID:
42618876
Bibliographic data and abstract were imported from PubMed on 20 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0